Registration - Open from 8:30 am - Closes at 11:00 am

All delegates must complete their registration process before the 11:00 AM cut-off time. Please arrive in a timely manner to allow for registration and to avoid any inconvenience. Delegates who arrive after the registration deadline will be refused entry to the event.

We appreciate your cooperation in helping us maintain the event's schedule and ensuring that everyone can fully participate in the Conference. If you have any questions or require assistance, our event staff will be available to assist you with the registration process.

Thank you for your understanding, and we look forward to an insightful and productive event together!

Chair Opening Address 

The technology to determine the genomics of a cancer from a blood sample using circulating tumour DNA also called liquid biopsy, has rapidly improved over the last 10 years. The NHS England pilot in lung cancer demonstrated how this could be implemented at scale to improve the care of patients, and reduced times to treatment in a cost-effective manner.

This has led the way for determining how we can implement these new technologies at scale and at pace but with key learnings as to patient identification, setting up sample collection pathway and result interpretation. These learnings and challenges that were met during the process of the pilot and NHS deployment will be discussed.

This panel discussion will explore actionable strategies to reduce health inequalities in cancer care. Experts will examine the multifaceted barriers to access, including socioeconomic, geographic, and cultural challenges, that contribute to disparities in cancer prevention, diagnosis, and treatment. By highlighting successful case studies and innovative interventions, the panel will provide insights into fostering equitable care for diverse populations.

Main Sponsor - Micrima

Morning Break

Chair Morning Reflection

Case Study - Biocartis

To discuss the experience to date of delivering point of care, physician-led genomic testing in the bronchoscopy room with same day results.

To discuss wider implications and considerations on whether this could be applicable on a wider footprint.

Case Study - C the Signs

• Detection challenges across the pathway – from non-specific symptoms in primary care to cancer-specific USC routes.
• Improving triage and decision-making through to referral quality – using digital tools to reduce delays and bottlenecks at the diagnostic stage.
• Making every contact count – harnessing technology to support a clinician’s assessment of risk, in the moment.

Challenges and opportunities in oncology care amidst NHS changes. From partnership opportunities to reduce waiting times, to innovative workforce models, to personalised case and integrative medicine.

Datar Cancer Genetics

The 2025 National Pancreatic Cancer Audit has just been published. Only 25% of diagnoses in England are at Stages 1 and 2 – 62% are at Stage 4. Average survival 1 year after diagnosis is 23%. Approximately 80% of patients are diagnosed when curative surgery is no longer possible and only 8% of those diagnosed get an operation.

Earlier and faster diagnosis is crucial to improving health outcomes. This involves effective case finding in primary care such as the Pancreatic Cancer Primary Care Case-Finding Pilot launched by the NHS this year.

We present a leading-edge liquid biopsy blood test, Datar Cancer Genetics’ TruBlood Pancreas, which has high sensitivity and specificity, and which can easily be administered in primary care. We published a paper on the performance of TruBlood Pancreas diagnostics last year with clinicians from London and around the world, which is available here.

Networking and Lunch

Chair Afternoon Address

Case Study - University Hospitals Southampton

Personalised Stratified Follow Up (PSFU/PIFU) is a vital part of delivering world class cancer services to people whilst addressing the challenges of demand and capacity throughout cancer pathways. The implementation of PSFU/PIFU pathways provides better care and experience for patients. By reducing the amount of time professionals spend seeing patients who are doing well after treatment, it also frees up professional’s time to focus on other parts of cancer pathway or on those patients with complex post treatment needs.

Case Study - Euronoxx Medical Group

Cone Beam Breast CT (CBBCT) is a non-compressing, true three-dimensional, low-radiation modality dedicated to breast imaging. Approved by the U.S. FDA, it has been implemented at nearly 40 sites across 9 countries and regions worldwide. This presentation will showcase clinical cases illustrating the role of CBBCT, both with and without contrast enhancement, and compare its efficiency and effectiveness against other mainstream modalities in breast cancer detection and diagnosis.

Luton is a diverse town with high deprivation and some of the lowest one-year cancer survival rates in the country. At the start of the project screening uptake was below the national average, and too many people were diagnosed late, often in hospital. The presentation explores how we used data to understand the medical, behavioural and social factors behind these outcomes. It will also describes our implementation approach, what impact it has had and what difference the project is making.

This panel at the NHS Oncology Conference will explore groundbreaking advancements in cancer treatment and aftercare, focusing on precision medicine, immunotherapies, and digital health tools. Experts will discuss targeted therapies tailored to genetic profiles, the transformative potential of immunotherapies, and the role of digital tools like remote monitoring and AI in personalised aftercare.

Panellists:

• Katey Evans, Personalised Care Navigator, Shrewsbury and Telford Hospitals Trust (Confirmed)
• Mr Ravi Chana, Executive Director, Diagnostics, ABHI (Association of British Healthtech Industries) (Confirmed)
• Mr John-Paul Crofton Biwer, Founder, Edge of Possible Consultancy (Confirmed)
   

Food, Drinks & Networking

End of Day